Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) closed a public offering on March 20, 2026, raising approximately $10.0 million gross by selling 6,666,667 common shares with accompanying Series G and Series H warrants at a combined price of $1.50 per share and warrant package.
The Series G and H warrants have a $1.50 exercise price; G warrants expire in five years and H warrants expire in 12 months. The company reported approximately $23 million cash post-close, which it believes funds operations into Q1 2027, and intends to use proceeds to fund R&D including the RECOVER-2 Phase 3 trial for brilaroxazine, plus working capital.
Positive
- Raised approximately $10.0M gross from the public offering
- Issued 6,666,667 common shares in the financing
- Proceeds earmarked to fund RECOVER-2 Phase 3 trial
- Cash balance of approximately $23M post-closing funds into Q1-2027
Negative
- Potential issuance of up to 13,333,334 shares from Series G and H warrants
- Combined potential dilution including sold shares and warrants could exceed 20M shares
- Series H warrants expire in 12 months, creating short-term overhang risk
News Market Reaction – RVPH
In the Mar 23 session, RVPH gained 11.62%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.2% during that session. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Offering pricing | Negative | -55.4% | Priced $10M unit offering with Series G and H warrants at $1.50. |
| Mar 18 | Proposed offering | Negative | -55.4% | Announced intention to conduct public stock and warrant offering for R&D funding. |
| Sep 18 | Offering pricing | Negative | -36.4% | Priced $9M public offering of 27M shares plus Series E and F warrants. |
| Sep 18 | Proposed offering | Negative | -36.4% | Proposed public offering of common stock and warrants under existing shelf registration. |
| Jun 26 | Offering pricing | Negative | -53.1% | Announced $10M offering of 20M shares with Series C and D warrants at $0.50. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related headlines have consistently triggered large negative moves, with past reactions between -36.43% and -55.43% on this tag.
Over the past year, Reviva has repeatedly used public offerings to fund its late-stage CNS pipeline. Offerings in June 2025, September 2025, and two financing headlines on March 18, 2026 each carried sizable negative price reactions, averaging about -47.37% for offering-tagged news. In parallel, the company advanced brilaroxazine with Phase 3 data publications and regulatory feedback requiring a second Phase 3 trial. Today’s closing of the $10 million offering extends that same capital-raising pattern to support RECOVER-2 and general operations.
Key Terms
series g warrants financial
series h warrants financial
common stock equivalents financial
phase 3 trial medical
prospectus supplement regulatory
shelf registration statement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the closing on March 20, 2026 of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warrants to purchase up to 6,666,667 shares of common stock (the "Series H Warrants"), at a combined offering price of
The Series G Warrants and the Series H Warrants have an exercise price of
The Company currently intends to use the net proceeds from the offering together with its existing cash and cash equivalents to fund research and development activities, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and other general corporate purposes.
Immediately following the closing of the offering, the Company has cash and cash equivalents of approximately
A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
The securities were offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024, and declared effective by the SEC on February 13, 2024. A prospectus supplement related to the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with the use of proceeds from the proposed offering, and the Company’s estimates and projections including regarding the Company’s current cash and projected cash runway. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s final prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2024 and Forms 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025 and the Company’s other filings with the SEC from time to time.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
REVIVA CONTACTS:
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
